Oral Ketamine for PTSD: 2026 Research Review

Most of the clinical evidence for ketamine in PTSD has come from IV infusion studies — controlled clinic environments where patients receive sub-anesthetic doses intravenously over 40 minutes. These trials have shown promising results, but they leave a significant question unanswered: can oral or sublingual ketamine, taken at home, produce meaningful benefits for PTSD patients?

A 2026 review by Forsyth and colleagues examines this question directly, synthesizing the emerging evidence on low-dose oral ketamine as a treatment for post-traumatic stress disorder.

Why the Route of Administration Matters for PTSD

For PTSD specifically, the treatment setting is not a minor detail. Many trauma survivors experience hypervigilance, difficulty trusting medical providers, and heightened distress in clinical environments. IV infusion clinics — with their medical equipment, needles, and unfamiliar surroundings — can be triggering for the very patients who might benefit most from ketamine.

This is different from the general oral vs. IV ketamine comparison, which typically focuses on bioavailability and peak plasma levels. For PTSD patients, the environment itself becomes part of the therapeutic equation.

What the Forsyth 2026 Review Found

The Forsyth review examined available studies on low-dose oral ketamine (typically 0.5–1.5 mg/kg) for PTSD symptoms, including both standalone pharmacological use and oral ketamine combined with psychotherapy. Key findings include:

1. Symptom reduction. Across the reviewed studies, patients receiving oral ketamine showed reductions in PTSD Checklist (PCL-5) scores, with effects typically emerging after 2–4 sessions and persisting through follow-up periods of 4–8 weeks.

2. Tolerability. Oral ketamine produced fewer hemodynamic changes and less intense dissociation compared to IV protocols. Side effects were generally mild — nausea, dizziness, and transient dissociative experiences — and most patients completed their treatment courses.

3. Patient preference. Where measured, PTSD patients expressed a preference for at-home oral administration over clinic-based IV infusions. The ability to be in a familiar, safe environment during the experience was cited as a significant factor.

4. Combination with therapy. Studies that paired oral ketamine with structured psychotherapy (such as trauma-focused CBT or EMDR preparation) showed larger effect sizes than pharmacological-only approaches, though the review notes that head-to-head comparisons are still lacking.

Oral vs. IV Ketamine for PTSD: A Different Comparison

The general pharmacokinetic differences between oral and IV ketamine are well documented: IV produces higher peak plasma levels and 100% bioavailability, while oral ketamine has roughly 20–25% bioavailability due to first-pass metabolism. This is often framed as a disadvantage of the oral route.

But for PTSD, the comparison looks different:

• Lower peak intensity may actually be preferable for trauma patients who are already managing hyperarousal and dissociative symptoms
• Gradual onset (30–45 minutes for oral vs. near-immediate for IV) gives patients more time to settle into the experience
• At-home setting eliminates the need to travel to and from an infusion clinic while in an altered state, and allows patients to control their environment
• Repeated dosing is more practical with oral formulations, supporting the kind of sustained treatment courses that PTSD may require

The Forsyth review notes that the oral route's lower bioavailability does not necessarily translate to lower clinical efficacy for PTSD, because the therapeutic mechanism may depend more on sustained NMDA receptor modulation and neuroplasticity than on peak drug levels.

The At-Home Advantage for Trauma Patients

For someone whose PTSD was caused by a medical event, an assault in an institutional setting, or military combat, the prospect of lying in a clinic chair with an IV line can be deeply uncomfortable. At-home treatment removes many of these barriers.

This is where the telehealth model becomes particularly relevant. With physician oversight via video, patients can undergo their ketamine sessions in a space where they feel safe — their own bedroom, a quiet room at home — while still receiving clinical monitoring and therapeutic support.

Isha Health's model was designed with this principle in mind: telehealth-delivered, at-home ketamine treatment that pairs sublingual ketamine with ongoing clinical support. For PTSD patients specifically, this combination of medical oversight and environmental comfort can make the difference between starting treatment and avoiding it.

Isha Health Outcomes

Across all conditions treated, Isha Health patients report an 88.8% improvement rate based on validated clinical measures. Our PTSD patients receive the same physician-led protocol, with treatment plans individualized to their symptom severity and treatment history.

To learn more about how ketamine works for PTSD, see our guide to ketamine therapy and our overview of ketamine for PTSD.

Further Reading

For broader context on ketamine and PTSD, including IV trial data and the role of ketamine-assisted psychotherapy, see:

• Ketamine and PTSD: Clinical Evidence
• Ketamine Therapy for PTSD
• Oral Ketamine vs. IV Infusion

---

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.